Article
Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer.
Bioorganic chemistry - 1 Sept 2023
An Baijiao, Fan Yangyang, Li Wei, Nie Wenyan, Nie Haoran, Wang Mengxuan, Feng Jie, Yao Han, Zhang Yin, Li Xingshu, Tian Geng
Abstract excerpt
For non-small cell lung cancer patients with dual mutations in EGFR and ALK, there are currently no effective therapies. Consequently, novel EGFR/ALK dual-target inhibitors are urgently needed for the treatment of NSCLC. Here, we designed a series of highly effective small molecule dual inhibitors of ALK and EGFR. The biological evaluation highlighted that most of these new compounds could effectively inhibit...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.